Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

48.62 +0.32 (+0.66%)
Streaming Delayed Price Updated: 1:14 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
54 55 Next >
Why Is Bristol-Myers Squibb (BMY) Stock Down Today?
Bristol-Myers Squibb stock is falling on Monday as investors in BMY shares react to two updates weighing on the company's stock. 
Via InvestorPlace
Why Is Pharma Giant Bristol-Myers Squibb Stock Trading Lower Today?
Shares of Bristol-Myers Squibb Company (NYSE: BMY) and  2seventy Bio Inc (NASDAQ: TSVT) fell after the companies' efforts to win expanded U.S. 
Via Benzinga
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
2 overlooked stocks that crushed earnings but traded lower
As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results 
Via MarketBeat
Exposures Product Safety
Looking At Bristol-Myers Squibb's Recent Unusual Options Activity
Via Benzinga
FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca
The FDA approved Bristol Myers Squibb And Co's (NYSE: BMY) Augtyro (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small  
Via Benzinga
Exposures Product Safety
Could Bristol-Myers Squibb Stock Help You Retire A Millionaire?
It isn't exactly a growth stock, but it has a few features that could make you richer. 
Via The Motley Fool
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)
From Bristol Myers Squibb
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
The Latest Analyst Ratings for Bristol-Myers Squibb
Via Benzinga
Decoding Bristol-Myers Squibb's Options Activity: What's the Big Picture?
Via Benzinga
Bristol Myers Squibb Proved in Q3 Why Its Diverse Portfolio Makes It a Solid Investment
The stock isn't nearly as risky as its low valuation suggests. 
Via The Motley Fool
Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030
EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NYSE:BMY),(NYSE:NVS),(NYSE:MRK),(OTCQX:RHHBY) EQNX::TICKER_END 
Via FinancialNewsMedia
High-yield, low-beta value plays for buy-and-hold investors
High-yield stocks that trade at a value and come with a lower-than-average beta can help mitigate portfolio volatility and boost returns over time. 
Via MarketBeat
Topics Economy
Exposures Economy
Looking At Bristol-Myers Squibb's Recent Unusual Options Activity
Via Benzinga
Is NYSE:BMY suited for dividend investing?
Is BRISTOL-MYERS SQUIBB CO (NYSE:BMY) suited for dividend investing? 
Via Chartmill
Debt-Fueled Buybacks: 3 Stocks Undeterred by Rising Rates
Share repurchases have slowed in 2023, partly due to the 1% tax. Here are three buybacks partially paid for with debt offerings. 
Via InvestorPlace
Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?
There's a lot more at stake than bragging rights. 
Via The Motley Fool
Bristol Myers Squibb to Participate in the 2023 Jefferies London Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
From Bristol Myers Squibb
Via Business Wire
Global Anal Cancer Market Size Expected to Reach $1.24 Billion In 2028 as Treatments Advance
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:BMY),(NASDAQ:GILD),(NYSE:MRK),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
3 No-Brainer Stocks to Buy With $500 Right Now
A reasonably modest amount of money can go a long way when it's invested in time-tested businesses with sustained catalysts. 
Via The Motley Fool
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Bristol Myers Squibb to Present Data from Innovative Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2023
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb’s First Disclosures and New Data at ASH 2023 Highlight Company’s Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Participate in the 2023 UBS BioPharma Conference
From Bristol Myers Squibb
Via Business Wire
Investor patience tested as pharmaceutical stocks take a tumble
The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector 
Via MarketBeat
Christopher Boerner To Take The Helm At Bristol Myers Squibb As Chair Of The Board, CEO
Via Benzinga
Bristol Myers Squibb Appoints Christopher Boerner, Ph.D., to Chair of the Board of Directors, Effective April 1, 2024
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes
From Bristol Myers Squibb
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
54 55 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.